AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

The article compares two pharmaceutical dividend stocks: AbbVie and Pfizer. AbbVie is a Dividend King with 50+ consecutive years of dividend increases, offering a 2.6% yield and $18 billion in free cash flow, with strong growth from immunology products like Rinvoq and Skyrizi. Pfizer is in recovery mode post-pandemic, offering a higher 6.2% dividend yield but with less consistent growth. The author recommends AbbVie as the better dividend buy due to its proven ability to grow dividends sustainably and demonstrated business resilience after losing Humira exclusivity.